KRAS and non-small cell lung carcinoma: Over the past years, it has become evident that NSCLC comprises common genetically driven alterations in oncogenes, such as EGFR (Epidermal Growth Factor Receptor, frequency 10–35%) and KRAS (frequency 15–25%) [3, 4].